MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.250
+0.160
+7.66%
After Hours: 2.250 0 0.00% 16:53 05/17 EDT
OPEN
2.024
PREV CLOSE
2.090
HIGH
2.290
LOW
2.010
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
4.260
52 WEEK LOW
0.5800
MARKET CAP
390.22M
P/E (TTM)
-3.7638
1D
5D
1M
3M
1Y
5Y
Outlook Therapeutics EPS misses by $0.01
Outlook Therapeutics (OTLK): FQ2 GAAP EPS of -$0.09 misses by $0.01.Cash and cash equivalents of $37.2MPress Release
Seekingalpha · 3d ago
BRIEF-Outlook Therapeutics Reports Q2 Loss Per Share Of $0.09
reuters.com · 3d ago
Outlook Therapeutics Q2 EPS $(0.09) Up From $(0.13) YoY
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last year.
Benzinga · 3d ago
Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update
-- Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021
GlobeNewswire · 3d ago
Outlook Therapeutics' Fiscal Q2 Loss Narrows, Operating Expenses Grow
MT Newswires · 3d ago
Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
ISELIN, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- ISELIN, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a�?�late...
GlobeNewswire · 5d ago
Outlook Therapeutics Stock Gives Every Indication Of Being Significantly Overvalued
GuruFocus News · 04/22 11:46
Aesthetic Medical International, Acorda Therapeutics leads healthcare gainers; Atea Pharmaceuticals, Inotiv among major losers
Gainers: Aesthetic Medical International (AIH) +14%, Acorda Therapeutics (ACOR) +13%, Outlook Therapeutics (OTLK) +12%, Organovo (ONVO) +12%, Asensus Surgical (ASXC) +11%.Losers: Atea Pharmaceuticals (AVIR) -7%, Inotiv NOTV -7%, Lava Therapeutics (LVTX) -7...
Seekingalpha · 04/21 15:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OTLK. Analyze the recent business situations of Outlook Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OTLK stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 59
Institutional Holdings: 12.06M
% Owned: 6.95%
Shares Outstanding: 173.43M
TypeInstitutionsShares
Increased
5
3.17M
New
11
2.70M
Decreased
4
16.68K
Sold Out
2
50.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Executive Director
Ralph Thurman
Chairman/Executive Director
Randy Thurman
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
Lawrence Kenyon
Chief Operating Officer
Terry Dagnon
Other
Jeff Evanson
Director
Gerd Auffarth
Director
Julian Gangolli
Director
Andong Huang
Independent Director
Yezan Haddadin
Independent Director
Kurt Hilzinger
Independent Director
Faisal Sukhtian
No Data
About OTLK
Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.

Webull offers kinds of Outlook Therapeutics Inc stock information, including NASDAQ:OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.